A phase II trial of cisplatin, docetaxel and bevacizumab followed by maintenance pemetrexed and bevacizumab in metastatic non-small-cell lung cancer
Not Applicable
- Conditions
- non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000004127
- Lead Sponsor
- Okayama Lung Cancer Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
pts with active co-morbidities including severe conditions of heart diseases, gastric ulcers, infections, uncontrollable diabetes, psychlogicai diseases, hypertension, active interstitial and hearing loss. pts with hemoptysis with 2.5mL or more bleeding tendency pts with radiological findings of tumor invasion to major vessels (i.e. aorta) and cavity lesion pts with bleeding tendency pts who need continuous use of antithrombotic agents pts with active other cancers that was detected within the past 5 years pts with massive pleural and cardiac effusion and ascites that need to be immediately treated pregnant women pts who need emergent irradiation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method